Original Publication Date: 1 November, 2016
Publication / Source: Future Oncology
Authors: Giuliano Palumbo, Giuseppe Di Lorenzo, Margaret Ottaviano & Vincenzo Damiano
The treatment of metastatic melanomas is one of the most interesting and exciting fields in oncology. In fact, worldwide, seven drugs, including three therapeutic immune checkpoint inhibitors and four BRAF-MEK blockers, have been approved for use since 2011. The interaction between the immune system and the melanoma has always been one of the peculiarities of this disease. The first attempt to develop a treatment that could improve the immunological activity against melanoma, through IL-2, provided encouraging results in terms of activity; however, the associated toxicity immediately discouraged routine use. In 2010, the advent of ipilimumab, an anti-CTLA-4 inhibitor, changed the whole scenario.